Results 171 to 180 of about 27,323 (260)

Abscopal Effect in Radiation Therapy: The Immune Mechanisms and Clinical Advances

MedComm, Volume 7, Issue 9, September 2026.
The schematic outlines the key events of the abscopal effect. (Ignition) Local radiotherapy (RT) induces the release of immunogenic signals from the tumor, leading to dendritic cell (DC) activation. (Orchestration) In the tumor‐draining lymph node (TDLN), DCs prime naive T cells into cytotoxic T lymphocytes (CTLs), a process modulated by regulatory T ...
Yihong Dong, Moran Chen, Xupeng Hou, Xiaoya Tang, Xiaoli Yu, Jing Liu   +5 more
wiley   +1 more source

C-type lectin domain family 5 member A-mediated activation of macrophages via a bispecific antibody enhances anti-HER2 therapy. [PDF]

J Immunother Cancer
Hou L, Jiao D, Dai H, Zhang J, Wang L, Gong X, Qi C, Guo X, Liu Z.   +8 more
europepmc   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Next-generation FVIIIa-mimetic bispecific antibody NXT007: evaluation in preclinical models of hemostasis and thrombosis. [PDF]

Blood Adv
Locke M, Albiez J, Receveur N, Marbach S, Frey N, Girotra M, Wyssenbach M, Bektic L, David T.   +8 more
europepmc   +1 more source

Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer

Histopathology, Volume 89, Issue 3, Page 456-466, September 2026.
c‐Met protein overexpression can be assessed before or after treatment in patients with non‐squamous NSCLC since most patients maintain a consistent c‐Met status. However, as targeted therapies may elevate c‐Met overexpression, retesting may be necessary for subsets of patients.
Alexis B Cortot, Romain Dubois, Valérie Grégoire, Jean‐Baptiste Gibier, Julien Labreuche, Virginie Deprez, Déborah Dubrulle, Thomas Chretien, Eric Wasielewski, Hélène Behal, Dai Feng, Amber Lind, Peter Ansell, Raphaële Thiébaut‐Millot, Carlos Hader   +14 more
wiley   +1 more source

Preclinical characterization of IBD0333, a novel CD24×4-1BB bispecific antibody with tumor-dependent agonistic activity for cancer immunotherapy. [PDF]

Antib Ther
Jiang DC, Zhou DD, Xu XR, Jiang XL, Yin LS, Zhong CY, Miao QF.   +6 more
europepmc   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

Transfusion, EarlyView.
Thane Kubik, Theodros Mamo, David H. McKenna   +2 more
wiley   +1 more source

Targeting progressive multiple sclerosis: Toward mechanism‐informed precision medicine

Journal of Internal Medicine, Volume 300, Issue 3, Page 238-257, September 2026.
Abstract Multiple sclerosis has undergone a therapeutic revolution over the past three decades. Randomized clinical trials and real‐world data demonstrate that modern disease‐modifying therapies substantially reduce relapse rates and acute inflammatory activity detected by magnetic resonance imaging (MRI).
Fredrik Piehl, Gonçalo Castelo‐Branco, Maja Jagodic, Tomas Olsson   +3 more
wiley   +1 more source

A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. [PDF]

Cell Oncol (Dordr)
Wang Y, Guo H, Han R, Wu Y, He T, Diao M, Xiong A, Zhou F, Cheng L, Zhao C, Li X, Zhou C.   +11 more
europepmc   +1 more source